Newron’s FY18 highlights the steady progression of its CNS R&D pipeline. STARS the pivotal Phase II/III (Sarizotan for Rett’s Syndrome) has completed enrolment and data are expected in Q419. Newron is planning to apply for a global filing and approval strategy once data are available. Evenamide (schizophrenia), developed internally through Newron’s ion channel discovery platform, could enable a paradigm shift in the treatment of refractory schizophrenia patients; in Q219
28 Mar 2019
Newron Pharmaceuticals - Moving towards R&D inflection points
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Newron Pharmaceuticals - Moving towards R&D inflection points
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
28 Mar 2019 -
Author:
Dr Susie Jana -
Pages:
15
Newron’s FY18 highlights the steady progression of its CNS R&D pipeline. STARS the pivotal Phase II/III (Sarizotan for Rett’s Syndrome) has completed enrolment and data are expected in Q419. Newron is planning to apply for a global filing and approval strategy once data are available. Evenamide (schizophrenia), developed internally through Newron’s ion channel discovery platform, could enable a paradigm shift in the treatment of refractory schizophrenia patients; in Q219